000282576 001__ 282576
000282576 005__ 20251219103450.0
000282576 0247_ $$2doi$$a10.1016/j.pbb.2025.174127
000282576 0247_ $$2pmid$$apmid:41218709
000282576 0247_ $$2ISSN$$a0091-3057
000282576 0247_ $$2ISSN$$a1873-5177
000282576 037__ $$aDZNE-2025-01336
000282576 041__ $$aEnglish
000282576 082__ $$a540
000282576 1001_ $$aRuoff, Lisa Katharina$$b0
000282576 245__ $$aLong-term thiethylperazine treatment in the Tg4-42 mouse model of Alzheimer's disease mouse: Therapeutic potential vs. adverse effects.
000282576 260__ $$aAmsterdam [u.a.]$$bElsevier Science$$c2025
000282576 3367_ $$2DRIVER$$aarticle
000282576 3367_ $$2DataCite$$aOutput Types/Journal article
000282576 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1766051185_31262
000282576 3367_ $$2BibTeX$$aARTICLE
000282576 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000282576 3367_ $$00$$2EndNote$$aJournal Article
000282576 520__ $$aAlzheimer's disease (AD) is a neurodegenerative disorder characterized by progressive cognitive decline and behavioral impairments. Thiethylperazine, a dopamine receptor antagonist with antiemetic and antidopaminergic properties, has been proposed as a potential therapeutic agent for AD. However, its impact on cognitive function in AD remains unclear.This study investigated the long-term effects of thiethylperazine on memory, anxiety-like behavior, motor function, and AD pathology in Tg4-42 mice, a model characterized by Aβ4-42 overexpression and progressive neurodegeneration. Additionally, the impact of prolonged thiethylperazine treatment on behavioral outcomes and cerebral glucose metabolism in healthy adult C57BL/6J wild-type (WT) mice were examined.Tg4-42 and WT mice were treated daily with 10 mg/kg thiethylperazine for 6 months, starting at 10 weeks of age. Memory, anxiety-related, and motor tests were performed at 7.5 months. Immunohistochemical analyses were conducted to quantify effects on Aβ pathology, neurogenesis, neuron number, and neuroinflammation. Additionally, 18F-FDG-PET imaging was used to evaluate metabolic activity in WT mice following treatment.Thiethylperazine improved recognition memory in Tg4-42 mice in the Novel Object Recognition test and exhibited anxiolytic properties. However, it impaired spatial learning in the Morris Water Maze (MWM), reduced locomotion, and failed to mitigate motor impairments. No effects on neuron loss or neuroinflammation were observed. In WT mice, thiethylperazine altered learning processes in the MWM, as indicated by shifts in search strategies, induced hypometabolism and increased neurogenesis.Although thiethylperazine offers mild cognitive benefits in Tg4-42, its adverse effects on learning strategies and locomotion raise questions about its potential as a therapeutic option for AD.
000282576 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000282576 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000282576 650_7 $$2Other$$a(18)F-FDG PET
000282576 650_7 $$2Other$$a(Up to seven): Tg4-42 mouse model
000282576 650_7 $$2Other$$aDopamine receptor antagonist
000282576 650_7 $$2Other$$aMorris water maze
000282576 650_7 $$2Other$$aNeurogenesis
000282576 650_7 $$2Other$$aNovel object recognition
000282576 7001_ $$aBänfer, Irina Wanda Helene$$b1
000282576 7001_ $$aLiedtke, Djavid Elias$$b2
000282576 7001_ $$aChina, Sofie Elena$$b3
000282576 7001_ $$0P:(DE-2719)2811317$$aWiltfang, Jens$$b4$$udzne
000282576 7001_ $$aBayer, Thomas A$$b5
000282576 7001_ $$aBock, Sören Frederik$$b6
000282576 7001_ $$aSpandau, Friederike$$b7
000282576 7001_ $$aBouter, Caroline$$b8
000282576 7001_ $$aBeindorff, Nicola$$b9
000282576 7001_ $$aBouter, Yvonne$$b10
000282576 773__ $$0PERI:(DE-600)2008734-2$$a10.1016/j.pbb.2025.174127$$gVol. 258, p. 174127 -$$p174127$$tPharmacology, biochemistry and behavior$$v258$$x0091-3057$$y2025
000282576 8564_ $$uhttps://pub.dzne.de/record/282576/files/DZNE-2025-01336%20SUP.docx
000282576 8564_ $$uhttps://pub.dzne.de/record/282576/files/DZNE-2025-01336_Restricted.pdf
000282576 8564_ $$uhttps://pub.dzne.de/record/282576/files/DZNE-2025-01336_Restricted.pdf?subformat=pdfa$$xpdfa
000282576 8564_ $$uhttps://pub.dzne.de/record/282576/files/DZNE-2025-01336%20SUP.doc
000282576 8564_ $$uhttps://pub.dzne.de/record/282576/files/DZNE-2025-01336%20SUP.odt
000282576 8564_ $$uhttps://pub.dzne.de/record/282576/files/DZNE-2025-01336%20SUP.pdf
000282576 909CO $$ooai:pub.dzne.de:282576$$pVDB
000282576 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811317$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000282576 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000282576 9141_ $$y2025
000282576 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2024-12-13$$wger
000282576 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-13
000282576 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-13
000282576 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-13
000282576 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-13
000282576 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-13
000282576 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-13
000282576 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-13
000282576 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-13
000282576 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-13
000282576 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bPHARMACOL BIOCHEM BE : 2022$$d2024-12-13
000282576 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-13
000282576 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-13
000282576 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2024-12-13
000282576 9201_ $$0I:(DE-2719)1410006$$kAG Wiltfang$$lMolecular biomarkers for predictive diagnostics of neurodegenerative diseases$$x0
000282576 980__ $$ajournal
000282576 980__ $$aVDB
000282576 980__ $$aI:(DE-2719)1410006
000282576 980__ $$aUNRESTRICTED